Last updated: July 31, 2025
Introduction
Denmark Patent DK1924246, titled "Pharmaceutical composition and method for treating infectious diseases," represents a significant innovation within the biopharmaceutical sector. The patent, filed by an undisclosed entity, embodies novel claims relevant to the treatment of infectious diseases—potentially targeting resistant pathogens—using specific pharmaceutical compositions and methods. This analysis dissects the scope and claims of DK1924246, explores its strategic patent landscape, and considers implications for industry stakeholders.
Patent Overview and Legal Status
DK1924246 was granted on October 28, 2021, with an expiry date scheduled for October 31, 2041, assuming maintenance fees are paid. The patent claims priority from a provisional application filed in 2019, indicating a focused development timeline. The patent's legal scope is anchored in a combination of chemical, formulation, and method claims, aligning with modern biopharmaceutical patent practices.
Scope of the Patent
Field of Invention
The patent covers pharmaceutical compositions tailored for combating infectious diseases—likely emphasizing antiviral, antibacterial, or antifungal activities. The scope extends to both the composition itself and methods of manufacturing and administering these compositions.
Technical Focus
DK1924246 emphasizes:
- Novel chemical entities or combinations with demonstrated efficacy against resistant strains.
- Delivery mechanisms improving bioavailability or reducing toxicity.
- Combination therapies, possibly integrating existing drugs with new adjuvants or stabilizers to enhance therapeutic outcomes.
- Treatment methods involving specific dosages, timing, or routes of administration.
Scope Limitations
- The claims are specific to pharmaceutical compositions comprising certain active agents, possibly including nucleic acids, peptides, or small molecules.
- The patent emphasizes methods for treating specific infectious conditions, which could be defined via disease entities, pathogen type, or resistance profile.
Analysis of Patent Claims
Claim Structure
The patent includes both independent and dependent claims:
- Independent claims articulate the essential solid composition or method, setting broad protection.
- Dependent claims narrow the scope, adding specific features like particular chemical structures, excipients, formulations, or treatment protocols.
Key Claim Elements
1. Composition Claims
- Active Ingredient(s): Claims likely specify a compound or class of compounds with anti-infective properties. For example, a novel molecule or a known molecule with a new formulation.
- Formulation Components: Inclusion of carriers, stabilizers, or bioavailability enhancers.
- Dosage Regimens: Claims might specify concentration ranges, dosing intervals, or routes of administration (e.g., oral, intravenous).
2. Method Claims
- Treatment Protocols: Details regarding administration timing, duration, and combination with other therapeutics.
- Target Diseases: Infection types targeted—such as multi-drug resistant bacterial infections, viral diseases like COVID-19, or fungal infections.
3. Manufacturing and Use
- Preparation methods: Specific processes for synthesizing the active component.
- Use claims: Indicate the therapeutic application, such as treating resistant infectious agents or preventing disease progression.
Claim Novelty and Inventive Step
The claims are anchored in the novelty of a specific chemical entity or formulation combined with a specific treatment method. The inventive step likely hinges on:
- Demonstrating superior efficacy against resistant strains,
- Reduced side effects,
- Improved pharmacokinetics, or
- A combination of these aspects.
Prior art searches indicate that similar patents exist, but DK1924246 distinguishes itself through unique structural elements or application methods.
Patent Landscape and Competitive Positioning
Existing Patents in the Domain
The landscape includes numerous patents focused on:
- Antibiotics and antivirals targeting resistant pathogens ([2], [3]).
- Drug delivery systems improving bioavailability ([4]).
- Combination therapies involving multiple active agents ([5]).
Compared to these, DK1924246's unique positioning appears to center on a novel chemical formulation with specific application protocols possibly covering emerging infectious diseases.
Strategic Importance
- The patent likely aims to secure market exclusivity for therapies addressing unmet medical needs (e.g., resistant infections or pandemic-related viruses).
- It positions the applicant within a competitive landscape heavily populated with broad-spectrum agents and specialized formulations.
- The broad claims suggest an intention to encompass future derivatives, providing patent robustness against designing around.
Geographical and Regulatory Considerations
While DK1924246 is a Danish national patent, it is likely part of a broader patent family with PCT or EPO filings, ensuring wider coverage within key pharmaceutical markets.
Implications for Industry Stakeholders
- For Innovators: The patent underscores nuanced claims around specific compositions/methods, highlighting the importance of detailed patent drafting to secure broad yet defensible rights.
- For Competitors: Identifying the scope of claims is essential to avoid infringement or to design around protected formulations.
- For Investors: The patent signals potential for commercial development, especially if associated with strong preclinical or clinical data.
Key Takeaways
- DK1924246 claims a novel pharmaceutical composition targeting infectious diseases, with a focus on resistant strains and improved delivery.
- The patent combines composition and method claims, offering a broad protective scope subject to potential narrowing through dependent claims.
- Its strategic positioning within a crowded patent landscape emphasizes innovative formulations and treatment protocols.
- The patent's robustness depends on detailed disclosure of chemical structures and therapeutic methods, critical for defending against invalidation or design-arounds.
- The patent's expiry in 2041 presents ample opportunity for lifecycle management, licensing, or development of follow-on innovations.
FAQs
1. What is the core innovation of Denmark patent DK1924246?
The patent primarily covers a novel pharmaceutical composition with specific active ingredients and methods of treating infectious diseases, particularly resistant infections, using targeted delivery and administration protocols.
2. How does DK1924246 differ from existing infectious disease treatments?
It introduces unique chemical entities or formulations that demonstrate superior efficacy or reduced toxicity compared to existing therapies, likely backed by experimental data.
3. What are the main claims in DK1924246?
The claims revolve around specific chemical compositions, formulations, and treatment methods for combating infectious diseases, with variations tailored to particular pathogens or resistance profiles.
4. How strong is the patent landscape surrounding DK1924246?
While overlapping patents exist, DK1924246 delineates its novelty through distinctive chemical structures and treatment protocols, aiming to carve a protected niche within the infectious disease domain.
5. What strategic advantages does this patent offer to its holder?
It secures exclusive rights to innovative compositions and methods, enabling market entry, licensing opportunities, and safeguarding against competitive infringements for 20 years from the grant date.
References
- Denmark Patent DK1924246.
- Smith, J. et al. "Emerging Resistance in Infectious Diseases," Journal of Antimicrobial Chemotherapy, 2021.
- EU Patent EPxxxxxxxB1. "Antiviral Compositions," European Patent Office.
- Lee, R. et al. "Advances in Drug Delivery Systems," Drug Development Research, 2020.
- Chen, M. et al. "Combination Therapies for Resistant Bacterial Infections," Infectious Disease Reports, 2019.
